| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10742362 | Journal of Geriatric Oncology | 2016 | 8 Pages |
Abstract
Biosimilar monoclonal antibodies are being developed globally to meet clinical demand in oncology and potentially provide greater access to biologic therapies for patients with cancer, including older patients. In this supplement, we present an overview of the development, approval requirements, and characteristics of biosimilar monoclonal antibodies that may help practicing oncologists and other healthcare providers to acquire familiarity with this new group of therapeutic biologic agents. Furthermore, we review and discuss some of the challenges and potential strategies for the management of older patients with cancer, who represent an increasing population in many countries.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Stuart M. Lichtman, Thomas Reske, Ira A. Jacobs,